Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2025 performance met market expectations, with revenue of 15.71 billion yuan, a year-on-year increase of 16.83%, and a net profit attributable to shareholders of 2.36 billion yuan, up 98.14% year-on-year [9] - The report highlights the positive trends in multiple business segments, particularly in the negative electrode sector, which is expected to contribute significantly to growth in 2026 [9] - The company is actively advancing the development and production of high-capacity negative electrodes and other innovative materials, which are anticipated to drive future revenue growth [9] Financial Summary - Total revenue projections for the company are as follows: 13.45 billion yuan in 2024, 15.71 billion yuan in 2025, 20.97 billion yuan in 2026, 26.59 billion yuan in 2027, and 33.84 billion yuan in 2028, with respective year-on-year growth rates of -12.33%, 16.83%, 33.49%, 26.81%, and 27.24% [1] - Net profit attributable to shareholders is forecasted to be 1.19 billion yuan in 2024, 2.36 billion yuan in 2025, 3.33 billion yuan in 2026, 4.38 billion yuan in 2027, and 5.35 billion yuan in 2028, with year-on-year growth rates of -37.72%, 98.14%, 41.18%, 31.57%, and 22.05% respectively [1] - The report projects an EPS of 0.56 yuan for 2024, increasing to 1.10 yuan in 2025, 1.56 yuan in 2026, 2.05 yuan in 2027, and 2.50 yuan in 2028 [1] - The company is expected to maintain a P/E ratio of 49.45 in 2024, decreasing to 24.96 in 2025, 17.68 in 2026, 13.44 in 2027, and 11.01 in 2028 [1]
璞泰来(603659):业绩符合市场预期,多业务板块持续向好